Table 1 Baseline characteristics of patients in this study

From: Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer

 

Total

Number of patients

103

Median age (range), years

62.0 (26–81)

Gender (%)

Male

65 (68.0)

Female

38 (32.0)

ECOG PS (%)

0–1

97 (94.2)

2

6 (5.8)

Primary site (%)

Colon

52 (50.5)

Rectum

51 (49.5)

Histological type (%)

Well, mod

88 (85.4)

Por, sig

14 (13.6)

Muc

1 (1.0)

Number of metastatic site (%)

1

29 (28.2)

⩽2

38 (71.6)

Treatment lines (%)

Second

9 (8.7)

Third

67 (65.1)

⩽Fourth

27 (26.2)

Regimen of chemotherapy (%)

Combination

82 (79.6)

Monotherapy

21 (20.4)

Anti-EGFR antibodies (%)

Cetuximab

83 (80.6)

Patinimumab

20 (19.4)

Subsequent treatment (%)

Yes

32 (31.1)

No

81 (68.9)

  1. Abbreviations: ECOG PS=Eastern Cooperative Oncology Group Performance Status; EREG=epiregulin; HGF=hepatocyte growth factor; mod=moderately differentiated adenocarcinoma; muc=mucinous adenocarcinoma; por=poorly differentiated adenocarcinoma; sig=signet ring cell carcinoma; well=well differentiated adenocarcinoma.
  2. P-value: significant difference is <0.05.
Back to article page